Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, non-randomized and single-center phase II clinical study,
to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib
in patients with advanced intrahepatic cholangiocarcinoma (ICC).